AML Cytogenetics 3

This panel is essential for diagnosing AML by identifying specific chromosomal abnormalities and mutations that are characteristic of different subtypes of AML. Knowing the subtype helps in choosing the most effective treatment plan.

The panel provides information about the number and structure of chromosomes and identifies specific genetic mutations, namely AML-ETO, Inv(16), MLL, and BCR/ABL, which are associated with AML. This information is critical in establishing a diagnosis, predicting outcomes, and making treatment decisions.

No, fasting is not required for this test.

This test is generally ordered when someone has symptoms suggestive of leukemia or if a healthcare provider detects abnormal cells in a complete blood count (CBC). It’s also used to monitor the effectiveness of treatment.

Normal values would show no chromosomal abnormalities or mutations. The presence of abnormalities such as AML-ETO, Inv(16), MLL, or BCR/ABL is indicative of AML.

Knowing the specific chromosomal abnormalities present in your leukemia cells helps your doctor choose targeted therapies that are likely to be more effective in treating your specific subtype of AML.

If the test results are abnormal, it is important to consult a hematologist or oncologist who specializes in blood cancers.

BCR/ABL is a fusion gene that is often associated with Chronic Myeloid Leukemia (CML) but can also be seen in some cases of AML. The presence of BCR/ABL in AML can have implications for prognosis and treatment.

FISH, or Fluorescence In Situ Hybridization, is a test that maps the genetic material in human cells, including specific genes or portions of genes. In diagnosing AML, it is used to find specific changes in chromosomes and genes that might not be visible under a microscope.

Inv(16) is a chromosomal abnormality where part of chromosome 16 is inverted. It is one of the common abnormalities in AML and is associated with a particular subtype of the disease. It has specific implications for prognosis and treatment.

MLL stands for Mixed Lineage Leukemia, which is a gene that can be involved in chromosomal translocations in leukemia. The rearrangements involving the MLL gene are associated with various types of leukemia, including AML.

AML-ETO is a fusion gene resulting from a translocation between chromosomes 8 and 21. It is one of the most common chromosomal abnormalities in AML and is typically associated with a better prognosis.

The blood draw is relatively safe but may cause minor pain. When a bone marrow sample is needed, there may be pain at the site of the biopsy.

Recognizing the genetic alterations in Acute Myeloid Leukemia is imperative for optimal management of the condition. The AML Cytogenetics 3 panel is a highly valuable tool in the diagnostic process and plays a significant role in guiding therapeutic strategies. Continuous communication with your doctor and active participation in the management and treatment plan is essential for the best possible outcomes.